diclofenac has been researched along with Adverse Drug Event in 48 studies
Diclofenac: A non-steroidal anti-inflammatory agent (NSAID) with antipyretic and analgesic actions. It is primarily available as the sodium salt.
diclofenac : A monocarboxylic acid consisting of phenylacetic acid having a (2,6-dichlorophenyl)amino group at the 2-position.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In this survey, the prescribed dosage was reduced or discontinued in 150 and 56 patients, respectively, receiving celecoxib and diclofenac prescribed alone, as recorded in a Japanese database of adverse drug events." | 8.31 | Plasma and Hepatic Exposures of Celecoxib and Diclofenac Prescribed Alone in Patients with Cytochrome P450 2C9*3 Modeled after Virtual Oral Administrations and Likely Associated with Adverse Drug Events Reported in a Japanese Database. ( Adachi, K; Murayama, N; Nakano, H; Ohyama, K; Saito, Y; Sato, T; Shimizu, M; Tanaka, Y; Yamazaki, H, 2023) |
| "5% dimethyl sulfoxide (TDiclo) for the treatment of knee or hand osteoarthritis in persons aged 75 years or older." | 7.78 | Pooled safety analysis of diclofenac sodium topical solution 1.5% (w/w) in the treatment of osteoarthritis in patients aged 75 years or older. ( Fuller, P; Roth, SH, 2012) |
| " In this survey, the prescribed dosage was reduced or discontinued in 150 and 56 patients, respectively, receiving celecoxib and diclofenac prescribed alone, as recorded in a Japanese database of adverse drug events." | 4.31 | Plasma and Hepatic Exposures of Celecoxib and Diclofenac Prescribed Alone in Patients with Cytochrome P450 2C9*3 Modeled after Virtual Oral Administrations and Likely Associated with Adverse Drug Events Reported in a Japanese Database. ( Adachi, K; Murayama, N; Nakano, H; Ohyama, K; Saito, Y; Sato, T; Shimizu, M; Tanaka, Y; Yamazaki, H, 2023) |
| "5% dimethyl sulfoxide (TDiclo) for the treatment of knee or hand osteoarthritis in persons aged 75 years or older." | 3.78 | Pooled safety analysis of diclofenac sodium topical solution 1.5% (w/w) in the treatment of osteoarthritis in patients aged 75 years or older. ( Fuller, P; Roth, SH, 2012) |
| "The aim of this study was to investigate the type of common (occurring in >1% of patients) adverse reactions caused by diclofenac when given to children for acute pain." | 3.75 | Prospective observational study of adverse drug reactions to diclofenac in children. ( Howard, RF; Keady, S; Ooi, K; Savage, I; Standing, JF; Wong, IC, 2009) |
| "The risk of a newly diagnosed episode of upper gastrointestinal bleeding, acute liver and renal failure, agranulocytosis, aplastic anemia, severe skin disorders, and anaphylaxis was examined within 30 days after the first prescription for a low dose of diclofenac, naproxen, or ibuprofen in a cohort in the United Kingdom." | 3.70 | Low-dose diclofenac, naproxen, and ibuprofen cohort study. ( Duque-Oliart, A; García-Rodríguez, LA; Pérez-Gutthann, S; Varas-Lorenzo, C, 1999) |
| "Decisions to use or avoid nonsteroidal anti-inflammatory drugs (NSAIDs) for postsurgical pain are often influenced by concerns about bleeding and renal adverse effects." | 2.78 | Safety of a novel parenteral formulation of diclofenac after major orthopedic or abdominal/pelvic surgery in a population including anticoagulated, elderly or renally insufficient patients: an open-label, multiday, repeated dose clinical trial. ( Carr, DB; Chelly, JE; Lacouture, PG; Melson, TI; Paadre, S; Singla, SK, 2013) |
| " The commonest adverse event associated with TDiclo was dry skin (18." | 2.74 | Efficacy and safety of topical diclofenac containing dimethyl sulfoxide (DMSO) compared with those of topical placebo, DMSO vehicle and oral diclofenac for knee osteoarthritis. ( Bookman, AAM; Grierson, LM; Naseer, Z; Shainhouse, ZJ; Simon, LS, 2009) |
| "Concomitant treatment with drugs that inhibit drug metabolising enzymes and/or transporters, such as commonly prescribed statins and nonsteroidal anti-inflammatory drugs (NSAIDs), has been associated with prolonged drug exposure and increased risk of adverse drug reactions (ADRs) due to drug-drug interactions." | 2.72 | Drug-drug-gene interactions as mediators of adverse drug reactions to diclofenac and statins: a case report and literature review. ( Borić Bilušić, A; Božina, N; Božina, T; Domjanović, IK; Fistrek Prlić, M; Ganoci, L; Gvozdanović, K; Križ, T; Laganović, M; Simičević, L, 2021) |
| " Randomized, double-blind, placebo-controlled, parallel-group trials that assessed adverse events (AEs) with topical NSAIDs in patients with OA were eligible for inclusion." | 2.61 | Safety of Topical Non-steroidal Anti-Inflammatory Drugs in Osteoarthritis: Outcomes of a Systematic Review and Meta-Analysis. ( Beaudart, C; Bruyère, O; Charles, A; Cooper, C; Geerinck, A; Honvo, G; Leclercq, V; Rabenda, V; Reginster, JY; Thomas, T; Veronese, N, 2019) |
| "To evaluate the risk of adverse events (AEs) associated with topical diclofenac for the treatment of acute and chronic musculoskeletal conditions." | 2.47 | Safety profile of topical diclofenac: a meta-analysis of blinded, randomized, controlled trials in musculoskeletal conditions. ( Fotopoulos, G; Maibach, H; Taylor, RS, 2011) |
| " Therefore, we aimed to evaluate the overall incidence and patterns of adverse events (AEs), the effectiveness of aceclofenac CR, and the differences in incidence rates of the AEs based on each patient's baseline charateristics." | 1.72 | Safety and effectiveness of 4-week therapy with aceclofenac controlled release once a day. ( Abd El-Aty, AM; Bang, JS; Chung, YH; Jeong, JC; Jeong, JH; Jung, TW; Park, SY; Park, T, 2022) |
| " Thus, the aim of this study was to analyze the toxic effects of pharmaceuticals in non-standard endpoints on two macrophyte species, Lemna minor and Lemna gibba." | 1.51 | Evaluation of pharmaceutical toxic effects of non-standard endpoints on the macrophyte species Lemna minor and Lemna gibba. ( Alkimin, GD; Barata, C; Daniel, D; Frankenbach, S; Nunes, B; Serôdio, J; Soares, AMVM, 2019) |
| "Nonsteroidal anti-inflammatory drugs (NSAIDs), which are globally prescribed, exhibit mainly anti-inflammatory and analgesic effects but also can cause adverse effects including gastrointestinal erosions, ulceration, bleeding, and perforation." | 1.43 | (1)H-Nuclear magnetic resonance-based metabolic profiling of nonsteroidal anti-inflammatory drug-induced adverse effects in rats. ( Choi, KH; Chung, MW; Lee, HJ; Park, JH; Um, SY, 2016) |
| " Toxicity studies with Diclofenac, Paracetamol and Verapamil in both cell lines show dose-response characteristics and EC(50) values similar to hHeps." | 1.38 | Comparative analysis of phase I and II enzyme activities in 5 hepatic cell lines identifies Huh-7 and HCC-T cells with the highest potential to study drug metabolism. ( Dooley, S; Ehnert, S; Hao, L; Lin, J; Liu, L; Mühl-Benninghaus, R; Neumann, J; Nussler, AK; Nussler, N; Schyschka, L; Stöckle, U, 2012) |
| " We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts." | 1.37 | FDA-approved drug labeling for the study of drug-induced liver injury. ( Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011) |
| "We propose a practical group sequential method, a conditional sequential sampling procedure, to test if a drug of interest (D) leads to an elevated risk for an adverse event E compared with a comparison drug C." | 1.35 | A conditional sequential sampling procedure for drug safety surveillance. ( Li, L, 2009) |
| "In a number of adverse drug reactions leading to hepatotoxicity drug metabolism is thought to be involved by generation of reactive metabolites from nontoxic drugs." | 1.35 | Development of an in vitro assay for the investigation of metabolism-induced drug hepatotoxicity. ( Badolo, L; Dalgaard, L; Dubois, J; Hansen, SH; Otto, M, 2008) |
| "5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects." | 1.32 | Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. ( Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004) |
| "Erythromycin was associated with two deaths." | 1.29 | Drug associated hepatic reactions in New Zealand: 21 years experience. ( Pillans, PI, 1996) |
| "Several side effects of drugs observed in an office of a general practitioner are described." | 1.28 | [The family physician and drug side-effects. Observations from general practice--conclusions for general practice]. ( Stahl, H, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (4.17) | 18.7374 |
| 1990's | 2 (4.17) | 18.2507 |
| 2000's | 16 (33.33) | 29.6817 |
| 2010's | 23 (47.92) | 24.3611 |
| 2020's | 5 (10.42) | 2.80 |
| Authors | Studies |
|---|---|
| Matthews, EJ | 1 |
| Kruhlak, NL | 1 |
| Weaver, JL | 1 |
| Benz, RD | 1 |
| Contrera, JF | 1 |
| Pedersen, JM | 1 |
| Matsson, P | 1 |
| Bergström, CA | 1 |
| Norinder, U | 1 |
| Hoogstraate, J | 1 |
| Artursson, P | 1 |
| Chen, M | 1 |
| Vijay, V | 1 |
| Shi, Q | 2 |
| Liu, Z | 2 |
| Fang, H | 2 |
| Tong, W | 2 |
| Ding, D | 1 |
| Kelly, R | 1 |
| Sakatis, MZ | 1 |
| Reese, MJ | 1 |
| Harrell, AW | 1 |
| Taylor, MA | 1 |
| Baines, IA | 1 |
| Chen, L | 1 |
| Bloomer, JC | 1 |
| Yang, EY | 1 |
| Ellens, HM | 1 |
| Ambroso, JL | 1 |
| Lovatt, CA | 1 |
| Ayrton, AD | 1 |
| Clarke, SE | 1 |
| Chen, ES | 1 |
| Lee, CL | 1 |
| Tsui, KC | 1 |
| Huang, CS | 1 |
| Alorabi, M | 1 |
| Cavalu, S | 1 |
| Al-Kuraishy, HM | 1 |
| Al-Gareeb, AI | 1 |
| Mostafa-Hedeab, G | 1 |
| Negm, WA | 1 |
| Youssef, A | 1 |
| El-Kadem, AH | 1 |
| Saad, HM | 1 |
| Batiha, GE | 1 |
| Jeong, JC | 1 |
| Chung, YH | 1 |
| Park, T | 1 |
| Park, SY | 1 |
| Jung, TW | 1 |
| Abd El-Aty, AM | 1 |
| Bang, JS | 1 |
| Jeong, JH | 1 |
| Adachi, K | 1 |
| Ohyama, K | 1 |
| Tanaka, Y | 1 |
| Nakano, H | 1 |
| Sato, T | 1 |
| Murayama, N | 1 |
| Shimizu, M | 1 |
| Saito, Y | 1 |
| Yamazaki, H | 1 |
| Božina, N | 1 |
| Ganoci, L | 1 |
| Simičević, L | 1 |
| Gvozdanović, K | 1 |
| Domjanović, IK | 1 |
| Fistrek Prlić, M | 1 |
| Križ, T | 1 |
| Borić Bilušić, A | 1 |
| Laganović, M | 1 |
| Božina, T | 1 |
| Ryu, B | 1 |
| Kim, CY | 1 |
| Oh, H | 1 |
| Kim, U | 1 |
| Kim, J | 1 |
| Jung, CR | 1 |
| Lee, BH | 1 |
| Lee, S | 1 |
| Chang, SN | 1 |
| Lee, JM | 1 |
| Chung, HM | 1 |
| Park, JH | 2 |
| Breivik, H | 1 |
| Alkimin, GD | 1 |
| Daniel, D | 1 |
| Frankenbach, S | 1 |
| Serôdio, J | 1 |
| Soares, AMVM | 1 |
| Barata, C | 1 |
| Nunes, B | 1 |
| Honvo, G | 1 |
| Leclercq, V | 1 |
| Geerinck, A | 1 |
| Thomas, T | 1 |
| Veronese, N | 1 |
| Charles, A | 1 |
| Rabenda, V | 1 |
| Beaudart, C | 1 |
| Cooper, C | 1 |
| Reginster, JY | 1 |
| Bruyère, O | 1 |
| Chelly, JE | 1 |
| Singla, SK | 1 |
| Melson, TI | 1 |
| Lacouture, PG | 1 |
| Paadre, S | 1 |
| Carr, DB | 1 |
| Inoue, T | 1 |
| Iijima, H | 1 |
| Arimitsu, J | 1 |
| Hagihara, K | 1 |
| Kawai, S | 1 |
| Shiraishi, E | 1 |
| Hiyama, S | 1 |
| Mukai, A | 1 |
| Shinzaki, S | 1 |
| Nishida, T | 1 |
| Ogata, A | 1 |
| Tsujii, M | 1 |
| Takehara, T | 1 |
| Li, J | 1 |
| Xu, L | 1 |
| Shi, ZG | 1 |
| Hu, M | 1 |
| Um, SY | 1 |
| Chung, MW | 1 |
| Choi, KH | 1 |
| Lee, HJ | 1 |
| Haddad, C | 1 |
| Chosidow, O | 1 |
| Valeyrie-Allanore, L | 1 |
| Ghaleh, B | 1 |
| Legrand, T | 1 |
| Mockenhaupt, M | 1 |
| Barau, C | 1 |
| Khoudour, N | 1 |
| Sekula, P | 1 |
| Wolkenstein, P | 1 |
| Hulin, A | 1 |
| Altman, R | 1 |
| Barkin, RL | 1 |
| Davern, TJ | 1 |
| Chalasani, N | 1 |
| Simon, LS | 1 |
| Grierson, LM | 1 |
| Naseer, Z | 1 |
| Bookman, AAM | 1 |
| Shainhouse, ZJ | 1 |
| Li, L | 1 |
| Standing, JF | 1 |
| Ooi, K | 1 |
| Keady, S | 1 |
| Howard, RF | 1 |
| Savage, I | 1 |
| Wong, IC | 1 |
| Haag, G | 1 |
| Jansen, JP | 1 |
| Gaugris, S | 1 |
| Choy, EH | 1 |
| Ostor, A | 1 |
| Nash, JT | 1 |
| Stam, W | 1 |
| van der Linden, CM | 1 |
| Jansen, PA | 1 |
| van Marum, RJ | 1 |
| Grouls, RJ | 1 |
| Korsten, EH | 1 |
| Egberts, AC | 1 |
| Stirnimann, G | 1 |
| Kessebohm, K | 1 |
| Lauterburg, B | 1 |
| Taylor, RS | 1 |
| Fotopoulos, G | 1 |
| Maibach, H | 1 |
| Lin, J | 1 |
| Schyschka, L | 1 |
| Mühl-Benninghaus, R | 1 |
| Neumann, J | 1 |
| Hao, L | 1 |
| Nussler, N | 1 |
| Dooley, S | 1 |
| Liu, L | 1 |
| Stöckle, U | 1 |
| Nussler, AK | 2 |
| Ehnert, S | 1 |
| Garbe, E | 1 |
| Andersohn, F | 1 |
| Bronder, E | 1 |
| Klimpel, A | 1 |
| Thomae, M | 1 |
| Schrezenmeier, H | 1 |
| Hildebrandt, M | 1 |
| Späth-Schwalbe, E | 1 |
| Grüneisen, A | 1 |
| Mayer, B | 1 |
| Salama, A | 1 |
| Kurtal, H | 1 |
| Miyaji, Y | 1 |
| Makino, C | 1 |
| Kurihara, A | 1 |
| Suzuki, W | 1 |
| Okazaki, O | 1 |
| Mueller, D | 1 |
| Müller-Vieira, U | 1 |
| Biemel, KM | 1 |
| Tascher, G | 1 |
| Noor, F | 1 |
| Lee, CH | 1 |
| Wang, JD | 1 |
| Chen, PC | 1 |
| Sui, Q | 1 |
| Wang, B | 1 |
| Zhao, W | 1 |
| Huang, J | 1 |
| Yu, G | 1 |
| Deng, S | 1 |
| Qiu, Z | 1 |
| Lu, S | 1 |
| Roth, SH | 1 |
| Fuller, P | 1 |
| Boelsterli, UA | 1 |
| Lamabadusuriya, SP | 1 |
| Sathiadas, G | 1 |
| Ferrari, B | 1 |
| Mons, R | 1 |
| Vollat, B | 1 |
| Fraysse, B | 1 |
| Paxéus, N | 1 |
| Lo Giudice, R | 1 |
| Pollio, A | 1 |
| Garric, J | 1 |
| Fountoulakis, M | 1 |
| Drillia, P | 1 |
| Stamatelatou, K | 1 |
| Lyberatos, G | 2 |
| Dokianakis, SN | 1 |
| Kornaros, ME | 1 |
| Gómez-Lechón, MJ | 1 |
| Castell, JV | 1 |
| Donato, MT | 1 |
| Hewitt, NJ | 1 |
| de Kanter, R | 1 |
| LeCluyse, E | 1 |
| Otto, M | 1 |
| Hansen, SH | 1 |
| Dalgaard, L | 1 |
| Dubois, J | 1 |
| Badolo, L | 1 |
| Pillans, PI | 1 |
| Pérez-Gutthann, S | 1 |
| García-Rodríguez, LA | 1 |
| Duque-Oliart, A | 1 |
| Varas-Lorenzo, C | 1 |
| Stahl, H | 1 |
| Berbatis, CG | 1 |
| Hurley, SF | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Single Center, Randomized, Double-blind, Placebo-controlled 2-way Crossover Study to Investigate the Mechanism of Action of Etoricoxib in Subjects With Osteoarthritis Knee Pain.[NCT01619150] | Phase 2 | 39 participants (Actual) | Interventional | 2012-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
10 reviews available for diclofenac and Adverse Drug Event
| Article | Year |
|---|---|
Drug-drug-gene interactions as mediators of adverse drug reactions to diclofenac and statins: a case report and literature review.
Topics: Diclofenac; Drug Interactions; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Hydr | 2021 |
Safety of Topical Non-steroidal Anti-Inflammatory Drugs in Osteoarthritis: Outcomes of a Systematic Review and Meta-Analysis.
Topics: Administration, Cutaneous; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Drug-Related Side Ef | 2019 |
Topical therapy for osteoarthritis: clinical and pharmacologic perspectives.
Topics: Administration, Cutaneous; Anti-Inflammatory Agents, Non-Steroidal; Capsaicin; Diclofenac; Drug-Rela | 2009 |
Drug-induced liver injury in clinical trials: as rare as hens' teeth.
Topics: Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Diclofenac; Drug-Related Side Effe | 2009 |
[Self-medication of primary headaches].
Topics: Acetaminophen; Analgesics; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Diclof | 2009 |
Liver injury caused by drugs: an update.
Topics: Acetaminophen; Adaptive Immunity; Analgesics, Non-Narcotic; Antitubercular Agents; Apoptosis; Chemic | 2010 |
Safety profile of topical diclofenac: a meta-analysis of blinded, randomized, controlled trials in musculoskeletal conditions.
Topics: Administration, Topical; Algorithms; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Double-Bli | 2011 |
Diclofenac-induced liver injury: a paradigm of idiosyncratic drug toxicity.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Chemical and Drug Induced Liver Injury; Diclofenac | 2003 |
Hepatocytes--the choice to investigate drug metabolism and toxicity in man: in vitro variability as a reflection of in vivo.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Biotransformation; Cells, Cultured; Cytochrome P-450 Enzyme | 2007 |
Induction of drug metabolizing enzymes: a survey of in vitro methodologies and interpretations used in the pharmaceutical industry--do they comply with FDA recommendations?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cell Culture Techniques; Cells, Cultured; Data Collection; | 2007 |
3 trials available for diclofenac and Adverse Drug Event
35 other studies available for diclofenac and Adverse Drug Event
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Dru | 2004 |
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Bi | 2008 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Des | 2011 |
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; Da | 2011 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme | 2012 |
Diclofenac-induced adverse drug reactions and hyperbilirubinemia caused by a variant gene.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Drug-Related Side Effects and Adverse Reactions | 2022 |
Pentoxifylline and berberine mitigate diclofenac-induced acute nephrotoxicity in male rats via modulation of inflammation and oxidative stress.
Topics: Animals; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Berberine; Diclofenac; D | 2022 |
Safety and effectiveness of 4-week therapy with aceclofenac controlled release once a day.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Delayed-Action Preparations; Diclofenac; Double-Blind Metho | 2022 |
Plasma and Hepatic Exposures of Celecoxib and Diclofenac Prescribed Alone in Patients with Cytochrome P450 2C9*3 Modeled after Virtual Oral Administrations and Likely Associated with Adverse Drug Events Reported in a Japanese Database.
Topics: Administration, Oral; Celecoxib; Cytochrome P-450 CYP2C9; Cytochrome P-450 Enzyme System; Diclofenac | 2023 |
Development of an alternative zebrafish model for drug-induced intestinal toxicity.
Topics: Animal Testing Alternatives; Animals; Caco-2 Cells; Diclofenac; Drug-Related Side Effects and Advers | 2018 |
A case-history illustrates importance of knowledge of drug-interactions when pain-patients are prescribed non-pain drugs for co-morbidities.
Topics: Aged; Comorbidity; Diclofenac; Drug Interactions; Drug-Related Side Effects and Adverse Reactions; F | 2017 |
Evaluation of pharmaceutical toxic effects of non-standard endpoints on the macrophyte species Lemna minor and Lemna gibba.
Topics: Acetaminophen; Anthocyanins; Aquatic Organisms; Araceae; Carotenoids; Catalase; Chlorophyll A; Chlor | 2019 |
A novel two-dimensional liquid chromatographic system for the online toxicity prediction of pharmaceuticals and related substances.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Carbazoles; Chlorophyta; Chromatography, Liquid; C | 2015 |
(1)H-Nuclear magnetic resonance-based metabolic profiling of nonsteroidal anti-inflammatory drug-induced adverse effects in rats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Cyclooxygenase 2 Inhibitors; D | 2016 |
Are Idiopathic Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis Related to Drugs in Food? The Example of Phenylbutazone.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Calibration; Ch | 2017 |
A conditional sequential sampling procedure for drug safety surveillance.
Topics: Aged; Computer Simulation; Cyclooxygenase 2 Inhibitors; Diclofenac; Drug Evaluation; Drug-Related Si | 2009 |
Prospective observational study of adverse drug reactions to diclofenac in children.
Topics: Adverse Drug Reaction Reporting Systems; Child; Child, Preschool; Confidence Intervals; Diclofenac; | 2009 |
Cost effectiveness of etoricoxib versus celecoxib and non-selective NSAIDS in the treatment of ankylosing spondylitis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Bayes Theorem; Celecoxib; Cost-Benefit Analysis; Cyclooxyge | 2010 |
Recurrence of adverse drug reactions following inappropriate re-prescription: better documentation, availability of information and monitoring are needed.
Topics: Adverse Drug Reaction Reporting Systems; Aged, 80 and over; Diclofenac; Drug Prescriptions; Drug-Rel | 2010 |
Comparative analysis of phase I and II enzyme activities in 5 hepatic cell lines identifies Huh-7 and HCC-T cells with the highest potential to study drug metabolism.
Topics: Acetaminophen; Carcinoma, Hepatocellular; Cell Line, Tumor; Cells, Cultured; Cytochrome P-450 Enzyme | 2012 |
Drug induced immune haemolytic anaemia in the Berlin Case-Control Surveillance Study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anemia, Hemolytic, Autoimmune; Anti-Bacterial Agents; An | 2011 |
In vitro evaluation of the potential for drug-induced toxicity based on (35)S-labeled glutathione adduct formation and daily dose.
Topics: Diclofenac; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Glutathio | 2012 |
Biotransformation of diclofenac and effects on the metabolome of primary human hepatocytes upon repeated dose exposure.
Topics: 3-Hydroxybutyric Acid; Biotransformation; Cells, Cultured; Cytochrome P-450 Enzyme System; Diclofena | 2012 |
Case-crossover design: an alternative strategy for detecting drug-induced liver injury.
Topics: Adult; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Case-Control Studies; Chemica | 2012 |
Identification of priority pharmaceuticals in the water environment of China.
Topics: Anti-Bacterial Agents; Cephalexin; China; Diclofenac; Drug Utilization; Drug-Related Side Effects an | 2012 |
Pooled safety analysis of diclofenac sodium topical solution 1.5% (w/w) in the treatment of osteoarthritis in patients aged 75 years or older.
Topics: Administration, Topical; Aged; Aged, 80 and over; Analysis of Variance; Anti-Inflammatory Agents, No | 2012 |
Adverse drug reactions in children requiring hospital admission.
Topics: Adverse Drug Reaction Reporting Systems; Anti-Bacterial Agents; Aspirin; Child, Preschool; Developin | 2003 |
Environmental risk assessment of six human pharmaceuticals: are the current environmental risk assessment procedures sufficient for the protection of the aquatic environment?
Topics: Animals; Carbamazepine; Clofibric Acid; Diclofenac; Drug-Related Side Effects and Adverse Reactions; | 2004 |
Toxic effect of pharmaceuticals on methanogenesis.
Topics: Bacteria, Anaerobic; Biomass; Carbamazepine; Clofibric Acid; Diclofenac; Drug-Related Side Effects a | 2004 |
On the effect of pharmaceuticals on bacterial nitrite oxidation.
Topics: Bacteria, Anaerobic; Biodegradation, Environmental; Bioreactors; Carbamazepine; Cities; Clofibrate; | 2004 |
Development of an in vitro assay for the investigation of metabolism-induced drug hepatotoxicity.
Topics: Animals; Biological Assay; Biotransformation; Cell Death; Cell Line; Cyclophosphamide; Diclofenac; D | 2008 |
Drug associated hepatic reactions in New Zealand: 21 years experience.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Age Factors; Aged; Aged, 80 and over; Amoxicillin; A | 1996 |
Low-dose diclofenac, naproxen, and ibuprofen cohort study.
Topics: Acute Kidney Injury; Adolescent; Adult; Aged; Aged, 80 and over; Anaphylaxis; Anti-Inflammatory Agen | 1999 |
[The family physician and drug side-effects. Observations from general practice--conclusions for general practice].
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Anaphylaxis; Anti-Inflammatory Agents, Non-Ste | 1989 |
Drug-bone marrow interactions.
Topics: Anemia, Aplastic; Australia; Bone Marrow Diseases; Diclofenac; Drug-Related Side Effects and Adverse | 1987 |